/ /

  • linkedin
  • Increase Font
  • Sharebar

    Dr. Mali's top 5 stories in ophthalmology in 2017 (so far)


    3) Ranibizumab gets new FDA approved indications 

    Whenever a vascular endothelial growth factor (VEGF) inhibitor gets a new FDA-approved clinical indication, it makes my top 5. If an anti-VEGF gets two new indications in the same year, you definitely make my top 3 and that is where ranibizumab (Lucentis, Genentech) sits on my list.

    In January of this year, ranibizumab became the first anti-VEGF therapy approved to treat patients with myopic choroidal neovascularization (mCNV) in the United States. To follow that up in April 2017, ranibizumab received FDA approval for the treatment of all forms of diabetic retinopathy.

    While I believe aflibercept (Eylea, Regeneron) will also eventually achieve these FDA-approved indications in the near future, these approvals for ranibizumab are a great step forward for the entire class of anti-VEGF inhibitors.

    Joshua Mali, MD
    Joshua Mali, MD, is a vitreoretinal surgeon at The Eye Associates, a private multispecialty ophthalmology practice in Sarasota, Florida.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results